Indicator Explainer
BCR/ABL1 Fusion Gene
A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of the ABL1 gene. There are 3 potential products that are formed depending on which BCR exon has the breakpoint. All of the protein products have constitutively active tyrosine kinase activity. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia.
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C94600. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-18. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.
Also Known As
References
- NCI Thesaurus 26.09d — BCR/ABL1 Fusion Gene (C94600)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C94600. NCI definition, reproduced without modification under CC BY 4.0.
- BCR::ABL1 e1a2 (p190)-Positive Myeloid Blast Neoplasm: Diagnostic Challenges in Distinguishing De Novo Acute Myeloid Leukemia From Previously Unrecognized Chronic Myeloid Leukemia in the Blast Phase. — Cureus, 2026-07-29 (PMID 42667018; literature)
- Case Report: Chronic myeloid leukemia masquerading as essential thrombocythemia in a child: the imperative for early BCR::ABL1 testing in isolated thrombocytosis. — Front Pediatr, 2026-07-20 (PMID 42548712; literature)
- Development and validation of an in-house one-step RT-qPCR method for the quantification of the BCR::ABL1 p210 transcripts. — Sci Rep, 2026-07-15 (PMID 42457813; literature)
- BCR-ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review. — Health Sci Rep, 2026-07-14 (PMID 42460242; literature)
- Development and Validation of a One-Step Multiplex RT-qPCR Assay for BCR-ABL1 Transcript Detection and Monitoring in Moroccan Chronic Myeloid Leukemia Patients. — Asian Pac J Cancer Prev, 2026-07-01 (PMID 42522808; literature)
- [Transcript distribution, sequence characteristics and clinical outcomes of rare transcript types of BCR::ABL1 fusion gene-positive leukemia patients]. — Zhonghua Yi Xue Za Zhi, 2026-05-01 (PMID 42103678; literature)
- Philadelphia chromosome-negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study. — Int J Hematol, 2026-04-22 (PMID 42020684; literature)
- Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients. — Int J Mol Sci, 2026-04-18 (PMID 42074261; literature)
- Acquired pericentric inversion of der(9) with BCR and ABL1 codeletion in chronic myeloid leukemia: a rare cytogenetic finding from Mali. — Mol Cytogenet, 2026-04-04 (PMID 41935330; literature)
- Interleukin signaling mitigates the inhibitory effects of combined Src/BCR-ABL1 blockade on T-cell activity in Philadelphia chromosome-positive acute lymphoblastic leukemia. — Haematologica, 2026-02-05 (PMID 41641639; literature)